Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc. (RPHM) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
rphm · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Reneo Pharmaceuticals, Inc.You RPHM | $61M | N/A | — | — |
 Achilles Therapeutics plc ACHL | $61M | N/A | — | -$1.74 |
 AlloVir, Inc. ALVR | $49M | N/A | — | -$0.28 |
 Heat Biologics, Inc. HTBX | $61M | N/A | — | -$1.41 |
 Kronos Bio, Inc. KRON | $54M | N/A | — | -$1.43 |
 Quince Therapeutics, Inc. QNCX | $6M | N/A | — | -$16.76 |
 Rein Therapeutics Inc. RNTX | $25M | N/A | — | -$1.96 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Reneo Pharmaceuticals, Inc. (RPHM) measures how much investors pay for each dollar of the company's trailing earnings. RPHM's current PE ratio of N/A is calculated by dividing its stock price of $18.20 by its TTM earnings per share of —.
Frequently asked questions
RPHM pe ratio · 6 questionsRPHM's current PE ratio is N/A as of 2026-06-09, based on a stock price of $18.20 and TTM EPS of —. Data sourced from Financial Modeling Prep via RPHM's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Reneo Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09